Why has the Cochlear (ASX:COH) share price lost 7% in a month?

The hearing implant giant has had a difficult run of late…

| More on:
a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Ltd (ASX: COH) share price started off the week's trading in the red but clawed back 1.88% yesterday to finish at $219.29.

That ends a difficult month for the manufacturer of the revolutionary cochlear hearing implant. The company's share price has slipped a further 7.6% out of the money in the last month, well ahead of the S&P/ASX 200 Index (ASX: XJO)'s loss of just 0.39% in that time.

Whilst there's been no market sensitive information for the company as of late, it's worthwhile taking a look at what's driving Cochlear shares lately.

Why has the Cochlear share price dropped 10% this past month?

If we take a step back and look at what's happened even earlier than September, it's clear Cochlear shares have been stuck in a descending channel since the company released its FY21 earnings results on 20 August.

In its report for FY21, Cochlear recognised a series of positive growth levers that translated directly to its financial performance. For instance, implant unit sales grew 15% year on year to 36,546 while sales revenue came in 10% higher from last year.

This carried through to Cochlear's bottom line. The company recorded a 54% year on year increase in underlying net profit – ahead of company guidance – and a corresponding 60% increase in its full year dividend to $2.55 per share.

These are undoubtedly positive results. However, at the time, the market was left searching for more. It seemed the company's earnings figures – whilst favourable on an absolute basis – where well behind consensus forecasts.

Failing to meet the forecasts of analysts at research and investment firms at earnings time generally spells bad news for a company's share price.

Numerous studies have shown companies who 'miss' analyst's published forecasts during earnings season tend not to perform too well after the fact. That's because investors tend to reward companies who post stronger than expected earnings, anticipating these to carry higher valuations into the future.

By the time September arrived, the Cochlear share price had already given back around 10% since its earnings results roughly two weeks earlier.

A regain in confidence, and perhaps some investors seeing a bargain in the cheaper Cochlear share price, helped prop the company's shares back towards the August highs. However, an announcement late last month regarding a potential patent infringement sent prices marching back down.

According to the University of Pittsburgh, it believes Cochlear has infringed on one of its patents, although the company claims the patent in question is invalid.

Nonetheless, investors were quick to punish Cochlear again, sending its shares a further 9% further into the red. That's a $22 per share loss in a matter of weeks, just to show the rate of decline.

It's also worth noting that the S&P/ASX 200 Health Care index (XHJ) is also 5.61% into the red over the past month as well, indicating weakness in the broader ASX healthcare sector lately.

It appears these factors are weighing on the Cochlear share price over the past few weeks.

Cochlear share price snapshot

The Cochlear share price has climbed almost 16.5% into the green this year to date.

However, over the last 12 months, it is just 1% ahead, well behind the benchmark index's return of around 19% in that time.

Should you invest $1,000 in Amazon right now?

Before you buy Amazon shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Amazon wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »